Author Archives: Margarida Azevedo, MSc

Study Suggests Male and Female Fertility and Longevity are Affected by Mitochondrial Genome Mutations

New evidence suggests that mutations in mitochondrial DNA (mtDNA) may significantly affect fertility and life expectancy, with important differences in male and female organisms. The study, led by PhD student Florencia Camus (School of Biological Sciences at Monash University) and entitled “Single Nucleotides in the mtDNA Sequence Modify Mitochondrial Molecular…

Foundation for Mitochondrial Medicine, UAB and Seahorse Bioscience Form Patient Care Clinical Program

Research efforts behind finding better solutions to mitochondrial diseases are receiving a boost with the newly founded Foundation for Mitochondrial Medicine Program at University of Alabama at Birmingham (UAB). The program was formed by a collaborative partnership between The Foundation for Mitochondrial Medicine (FMM), the University of Alabama at Birmingham (UAB) and Seahorse…

Alcohol Affects Mitochondria Due to Circadian Clock’s Disruption

Researchers may have finally confirmed the widely-held theory that there is a correlation between drinking alcohol and a higher risk of developing mitochondrial disease. New insights reveal that chronic drinking causes damage to the mitochondria, and consequently the liver, due to the effects of alcohol on the liver’s circadian clock.

Study Shows Altered Mitochondrial DNA Changes Precede Bioenergetic Dysfunction in Diabetic Nephropathy

Results from a recent study published in the journal EBioMedicine showed that altered mitochondrial DNA changes precede bioenergetic dysfunction and that patients with diabetic nephropathy (DN) have impaired mitochondrial metabolism compared to kidney disease. The results indicate that systemic mitochondrial dysfunction initiated by glucose induced altered…

MitoAction Energy Walk & 5K To Be Held in September

MitoAction Energy Walk & 5K, a well-established annual charity event within the mitochondrial disease community, will take place this year on Saturday, September 12. The event is designed to help raise awareness and funding to support patients who suffer from mitochondrial diseases. In addition to a 5K walk, the event meant to be a…

Reata Enrolls First Patient in RTA 408 Trial for Mitochondrial Myopathies

Irving, Texas-based Reata Pharmaceuticals has just announced the enrollment of the first patient in the company’s Phase II MOTOR clinical trial. This study will seek to determine the safety, tolerability and efficacy of Reata’s experimental RTA 408 Oral Capsules as a potential treatment for mitochondrial myopathies (MM). RTA-408 works to improve mitochondrial…